Join
Live feed
·
PRReleasevia Quantisnow
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

ByQuantisnow·Wall Street's wire, on your screen.
KTTA· Pasithea Therapeutics Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KTTA (Pasithea Therapeutics Corp.) and more on Quantisnow.